Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2012

View Archived Issues

Merck & Co. uncovers gene polymorphisms linked to MK-7246 pharmacokinetics

Fate Therapeutics discloses new hedgehog pathway activators

Canadian university patents new SHIP-1 modulators

Novartis discloses updated phase II data on secukinumab

Cardium Therapeutics begins phase III registration study

Korean trials assess two Lapscovery-based drugs

Galapagos receives milestone payment from Janssen Pharmaceutica

Addex Pharmaceuticals changes name

Ablynx extends global strategic Nanobody alliance

Abbott discloses new name for future research-based company

Medistem updates on endometrial regenerative cell therapy development

Treatment begins in global phase II/III hemophilia B trial

Flagyl approved for additional indication in Japan

NCI study reveals novel candidate biomarkers of hepatocellular carcinoma

Health Canada approves grass pollen immunotherapy

Green Cross clear to conduct GreenGene F study in U.S.

Merck & Co. presents new potential cancer therapies

Novel chemokine CCR4 receptor antagonists developed at GSK

New tyrosine-protein kinase inhibitors reported

Chroma Therapeutics designs new histone deacetylase inhibitors

Allergan scientists discover novel prostanoid receptor antagonists

Cerus gives update on INTERCEPT Blood System

Line extension for Taxol approved in Japan

Enrollment complete in phase II MN-221 trial

Noven completes phase III program for low-dose paroxetine mesilate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...